anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: BTRX-246040
Trial phase: Phase 2
SMILES: Cc1nn(-c2ncccc2CO)cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: 40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.

BTRX-246040 oral capsule(s): BTRX-246040 administered once daily to patients with MDD for 8 weeks
Eligibility criteria:
Inclusion Criteria:

Patients with a diagnosis of MDD as defined by DSM-5 criteria and have had at least 1 prior major depressive episode in the past 10 years
Patients must present with a new current episode of MDD and the duration of the current episode must be at least 4 weeks but not longer than 18 months.
At Visit 1 (screening) and Visit 2 (baseline), patients must have clinically significant depressive symptoms defined by tandem (investigator- and computer-administered) Montgomery-Asberg Depression Rating Scale (MADRS) total scores ≥ 26 with a difference of ≤ 7 points between the Investigator- and computer-administered MADRS total scores
Patients must have a CGI-S score ≥ 4 at Visit 2 (baseline).

Exclusion Criteria:

Patients who present with any current DSM-5 disorder other than MDD which is the focus of treatment.
Patients who are homicidal in the opinion of the Investigator or are at suicidal risk (any suicide attempts within 12 months prior to Visit 1 [screening] or any suicidal intent, including a plan, within 3 months prior to Visit 1 [screening]; C-SSRS answer of "YES" on item 4 or 5 [suicidal ideation]; Investigator- or computer-administered MADRS score of ≥ 5 on item 10 [suicidal thoughts]; by Investigator clinical evaluation).
Patients cannot have any history of substance or alcohol use disorder within 12 months prior to Visit 1 (screening) per DSM-5 criteria
Patients must not have a clinically significant comorbid disease.
Intervention: Bavisant
Trial phase: Phase 2
SMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Experimental treatment

BEN-2001: Bavisant dihydrochloride monohydrate for oral use
Eligibility criteria:
Inclusion Criteria:

Subjects of either sex aged 50 to 80 years *Subjects with previous diagnosis of Parkinson's disease (following the UK Parkinson's disease society brain bank clinical diagnostic criteria)*
Subjects capable of understanding and complying with protocol requirements
Subjects with medical history of excessive daytime sleepiness

Exclusion Criteria:

Subjects with excessive daytime sleepiness due to conditions other than Parkinson's disease (including narcolepsy)
Subjects with clinical evidence of depression with significant psychiatric comorbidities (Hamilton Rating Scale for Depression - HAM-D score greater than or equal to 17; with or without treatment)
Subjects with evidence of significant fatigue (Fatigue Severity Scale - FSS greater than or equal to 36
Subjects with known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.
Subjects with known allergies or hypersensitivity to Bavisant or any of its excipients.
Subjects who are pregnant or lactating.
Intervention: Bavisant
Trial phase: Phase 2
SMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Experimental treatment

BEN-2001: Bavisant dihydrochloride monohydrate for oral use
Eligibility criteria:
Inclusion Criteria:

Subjects of either sex aged 50 to 80 years *Subjects with previous diagnosis of Parkinson's disease (following the UK Parkinson's disease society brain bank clinical diagnostic criteria)*
Subjects capable of understanding and complying with protocol requirements
Subjects with medical history of excessive daytime sleepiness

Exclusion Criteria:

Subjects with excessive daytime sleepiness due to conditions other than Parkinson's disease (including narcolepsy)
Subjects with clinical evidence of depression with significant psychiatric comorbidities (Hamilton Rating Scale for Depression - HAM-D score greater than or equal to 17; with or without treatment)
Subjects with evidence of significant fatigue (Fatigue Severity Scale - FSS greater than or equal to 36
Subjects with known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.
Subjects with known allergies or hypersensitivity to Bavisant or any of its excipients.
Subjects who are pregnant or lactating.
Intervention: Sugammadex
Trial phase: Phase 4
ATC code: V03AB35
SMILES: O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: Patients received 2 mg/kg Sugammadex intravenously once in the postoperative period in a blinded fashion.
Eligibility criteria:
Inclusion Criteria:

All elective ARV, CABG cases, on-pump or off-pump, and CABG/AVR in adult patients with preoperative left ventricular ejection fraction (LVEF) ≥45%.

Exclusion Criteria:

Emergency/unplanned cases.
EF<45% or moderate /severe RV dysfunction.
Estimated GFR < 30 mL/min.
Patients on supplemental oxygen at baseline (home oxygen).
BMI>40 (calculated as the patient's weight in kilograms divided by the square of the patient's height in meters).
Patients with chronic opioid use preoperatively.
Patients with known neuromuscular disorders preoperatively.
Patients with a known sensitivity to Rocuronium or to Sugammadex.
Patients with known cognitive deficits preoperatively.

Exclusions after recruitment but prior to randomization:

Postoperative Bleeding (chest tube output >100cc/hr ).
Treatment of anaphylactoid reaction intraoperatively.
Patient's temperature<35.5 or >38.3 degree Celsius at the time of ICU arrival.
Determination that the patient will require prolonged mechanical ventilation possibly requiring muscle relaxation based on the intraoperative course and clinical judgment of the study PI or collaborating intensivists.
Intraoperative hypoxia or on arrival to the ICU. (Please see Study Flowchart).
Cardiac arrest.
Sudden arrhythmia (Ventricular tachycardia runs/sudden bradycardia with improper pacemaker detection/function) precluding fast-track extubation protocol.
Need for inotrope initiation precluding fast-track protocol.
Postoperative ST changes.
Intervention: Warfarin
Trial phase: Phase 4
ATC code: B01AA03
SMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3

Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
Eligibility criteria:
3.1 Inclusion Criteria

To be eligible for this trial, patients must meet all of the following criteria:

Have confirmed acute, symptomatic, first lower extremity proximal DVT and/or PE that is NOT associated with a transient risk factor.
Have completed an initial treatment course of oral anticoagulant therapy for 3-12 months and have a recommendation from their provider to continue anticoagulation indefinitely.
Have the capacity to understand and sign an informed consent form.
Be 18 years of age and older.
Under the direct care of a healthcare provider for treatment of VTE for the length of time in the study.

3.2 Exclusion Criteria

If a patient meets any of the following criteria, he or she may not be enrolled in the study:

Creatinine clearance (CrCl) < 30 mL/min as determined by Cockcroft-Gault formula documented within 3 months from date of consent
Significant liver disease (Child-Pugh B or C)
Concomitant use of medications that are strong P-glycoprotein or CYP3A4 inducers/inhibitors
Another indication for chronic therapeutic-dose anticoagulation, such as atrial fibrillation (i.e., rivaroxaban, 10 mg daily, or apixaban, 2.5 mg twice daily, would not be appropriate therapy)
A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome).
Life expectancy < 3 months
Currently pregnant or breast feeding
Unable / unwilling to pay for one (or more) of the treatment options
Active Cancer defined as:

Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or A hematologic malignancy not in complete remission

• Unwilling / unlikely to agree to follow up
Intervention: Apixaban
Trial phase: Phase 4
ATC code: B01AF02
SMILES: COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily

Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily
Eligibility criteria:
3.1 Inclusion Criteria

To be eligible for this trial, patients must meet all of the following criteria:

Have confirmed acute, symptomatic, first lower extremity proximal DVT and/or PE that is NOT associated with a transient risk factor.
Have completed an initial treatment course of oral anticoagulant therapy for 3-12 months and have a recommendation from their provider to continue anticoagulation indefinitely.
Have the capacity to understand and sign an informed consent form.
Be 18 years of age and older.
Under the direct care of a healthcare provider for treatment of VTE for the length of time in the study.

3.2 Exclusion Criteria

If a patient meets any of the following criteria, he or she may not be enrolled in the study:

Creatinine clearance (CrCl) < 30 mL/min as determined by Cockcroft-Gault formula documented within 3 months from date of consent
Significant liver disease (Child-Pugh B or C)
Concomitant use of medications that are strong P-glycoprotein or CYP3A4 inducers/inhibitors
Another indication for chronic therapeutic-dose anticoagulation, such as atrial fibrillation (i.e., rivaroxaban, 10 mg daily, or apixaban, 2.5 mg twice daily, would not be appropriate therapy)
A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome).
Life expectancy < 3 months
Currently pregnant or breast feeding
Unable / unwilling to pay for one (or more) of the treatment options
Active Cancer defined as:

Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or A hematologic malignancy not in complete remission

• Unwilling / unlikely to agree to follow up
Intervention: Rivaroxaban
Trial phase: Phase 4
ATC code: B01AF01
SMILES: O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily

Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily
Eligibility criteria:
3.1 Inclusion Criteria

To be eligible for this trial, patients must meet all of the following criteria:

Have confirmed acute, symptomatic, first lower extremity proximal DVT and/or PE that is NOT associated with a transient risk factor.
Have completed an initial treatment course of oral anticoagulant therapy for 3-12 months and have a recommendation from their provider to continue anticoagulation indefinitely.
Have the capacity to understand and sign an informed consent form.
Be 18 years of age and older.
Under the direct care of a healthcare provider for treatment of VTE for the length of time in the study.

3.2 Exclusion Criteria

If a patient meets any of the following criteria, he or she may not be enrolled in the study:

Creatinine clearance (CrCl) < 30 mL/min as determined by Cockcroft-Gault formula documented within 3 months from date of consent
Significant liver disease (Child-Pugh B or C)
Concomitant use of medications that are strong P-glycoprotein or CYP3A4 inducers/inhibitors
Another indication for chronic therapeutic-dose anticoagulation, such as atrial fibrillation (i.e., rivaroxaban, 10 mg daily, or apixaban, 2.5 mg twice daily, would not be appropriate therapy)
A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome).
Life expectancy < 3 months
Currently pregnant or breast feeding
Unable / unwilling to pay for one (or more) of the treatment options
Active Cancer defined as:

Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or A hematologic malignancy not in complete remission

• Unwilling / unlikely to agree to follow up
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 89
Group description: Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).

Exparel 266 MG Per 20 ML Injection: Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Eligibility criteria:
Inclusion Criteria:

All patients undergoing elective laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass surgeries.
Fulfills NIH criteria for bariatric surgery

Exclusion Criteria:

Patients deemed not a candidate for laparoscopic bariatric surgery
Patients with previous bariatric or gastric surgeries.
BMI <35 and > 60 kg/m2
Preoperative inability to ambulate and confined to wheelchair.
American Society of Anesthesiologist (ASA) score >3
Concurrent ventral hernia repair or intraoperative extensive lysis of adhesions
Not able to understand informed consent, or unwilling to sign consent.
Not able to understand and read English
Currently pregnant or lactating.
Age <18 or >65
Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
Patients requiring opiate use within 30 days prior to time of surgery.
Patients with reported use of narcotics greater than 2 weeks in preceding year before surgery.
Patients with history of substance abuse, alcohol addiction
Patients with diagnosis of chronic pain, history of fibromyalgia, chronic regional pain syndrome (dystrophic pain syndrome).
Bupivacaine use within 96 hours before operation
Prisoners
Bariatric surgery operation >3 hours.
More than 5 laparoscopic incision sites used during surgery, conversion to open operation, placement of a feeding tube or drain.
Patients with renal failure or hepatic failure.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 90
Group description: 60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).

Bupivacaine: 60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Eligibility criteria:
Inclusion Criteria:

All patients undergoing elective laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass surgeries.
Fulfills NIH criteria for bariatric surgery

Exclusion Criteria:

Patients deemed not a candidate for laparoscopic bariatric surgery
Patients with previous bariatric or gastric surgeries.
BMI <35 and > 60 kg/m2
Preoperative inability to ambulate and confined to wheelchair.
American Society of Anesthesiologist (ASA) score >3
Concurrent ventral hernia repair or intraoperative extensive lysis of adhesions
Not able to understand informed consent, or unwilling to sign consent.
Not able to understand and read English
Currently pregnant or lactating.
Age <18 or >65
Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
Patients requiring opiate use within 30 days prior to time of surgery.
Patients with reported use of narcotics greater than 2 weeks in preceding year before surgery.
Patients with history of substance abuse, alcohol addiction
Patients with diagnosis of chronic pain, history of fibromyalgia, chronic regional pain syndrome (dystrophic pain syndrome).
Bupivacaine use within 96 hours before operation
Prisoners
Bariatric surgery operation >3 hours.
More than 5 laparoscopic incision sites used during surgery, conversion to open operation, placement of a feeding tube or drain.
Patients with renal failure or hepatic failure.
Intervention: Sugammadex Sodium
Trial phase: Phase 3
SMILES: O=C([O-])CCSCC1OC2OC3C(CSCCC(=O)[O-])OC(OC4C(CSCCC(=O)[O-])OC(OC5C(CSCCC(=O)[O-])OC(OC6C(CSCCC(=O)[O-])OC(OC7C(CSCCC(=O)[O-])OC(OC8C(CSCCC(=O)[O-])OC(OC9C(CSCCC(=O)[O-])OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 196
Group description: Sugammadex sodium 4mg/kg/IV after operation

Sugammadex Sodium: 1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.

2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.
Eligibility criteria:
Inclusion Criteria:

Gastric cancer patients with laparoscopic subtotal gastrectomy
19-75 years
Body mass index(BMI) > 25kg/m2
American Society of Anesthesiologists I-III

Exclusion Criteria:

American Society of Anesthesiologists Class IV
End stage renal disease (ESRD) patient
Patients with allergy to muscle relaxants
Patients with diseases that may affect muscle relaxation
Intervention: Sugammadex Sodium
Trial phase: Phase 3
SMILES: O=C([O-])CCSCC1OC2OC3C(CSCCC(=O)[O-])OC(OC4C(CSCCC(=O)[O-])OC(OC5C(CSCCC(=O)[O-])OC(OC6C(CSCCC(=O)[O-])OC(OC7C(CSCCC(=O)[O-])OC(OC8C(CSCCC(=O)[O-])OC(OC9C(CSCCC(=O)[O-])OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 196
Group description: Sugammadex sodium 2mg/kg/IV after operation

Sugammadex Sodium: 1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.

2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.
Eligibility criteria:
Inclusion Criteria:

Gastric cancer patients with laparoscopic subtotal gastrectomy
19-75 years
Body mass index(BMI) > 25kg/m2
American Society of Anesthesiologists I-III

Exclusion Criteria:

American Society of Anesthesiologists Class IV
End stage renal disease (ESRD) patient
Patients with allergy to muscle relaxants
Patients with diseases that may affect muscle relaxation
Intervention: Daptomycin
Trial phase: Phase 3
ATC code: J01XX09
SMILES: CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 195
Group description: Otic solution

DF289: 1 vial into the affected ear twice daily for 7 days
Eligibility criteria:
Inclusion Criteria:

Uncomplicated AOE of less tan 21 days, defined as a total symptom score of at least 2 for otalgia, 2 for edema and 1 for otorrhea
Brighton Grading of II or III
Culture-based diagnosis of acute bacterial otitis externa
Willingness to refrain from swimming through end of the study

Exclusion Criteria:

Previous episode of AOE within 4 weeks prior to enrollment, or 2 or more episodes of AOE within 6 months prior to the enrollment.
Tympanic membrane perforation
Any condition or situation likely to cause the patient to be unable or unwilling to comply with study treatment or attend all study visits
Any condition in the patient or parent/guardian that, in the judgment of the principal investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Intervention: Betamethasone Sodium Phosphate
Trial phase: Phase 3
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Otic solution

DF277: 1 vial into the affected ear twice daily for 7 days
Eligibility criteria:
Inclusion Criteria:

Uncomplicated AOE of less tan 21 days, defined as a total symptom score of at least 2 for otalgia, 2 for edema and 1 for otorrhea
Brighton Grading of II or III
Culture-based diagnosis of acute bacterial otitis externa
Willingness to refrain from swimming through end of the study

Exclusion Criteria:

Previous episode of AOE within 4 weeks prior to enrollment, or 2 or more episodes of AOE within 6 months prior to the enrollment.
Tympanic membrane perforation
Any condition or situation likely to cause the patient to be unable or unwilling to comply with study treatment or attend all study visits
Any condition in the patient or parent/guardian that, in the judgment of the principal investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Intervention: Fosaprepitant
Trial phase: Phase 4
SMILES: C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Patients receive fosaprepitant 150 mg intravenously (i.v.).
Eligibility criteria:
Inclusion Criteria:

Having a surgical procedure requiring general anesthesia, having a surgical procedure where neuromonitoing with somatosensory evoked potentials and motor evoked potentials neuromonitoring is requested by the surgical team

Exclusion Criteria:

Patient refusal, allergy to the drug or any of its excipients, pre-operative motor or sensory deficit